PRESS RELEASE published on 08/15/2024 at 13:03, 3 months 8 days ago CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma CureVac initiates Part B of Phase 1 study for cancer vaccine CVGBM in resected glioblastoma patients, focusing on safety and immunogenicity CureVac MRNA Glioblastoma CVGBM Phase 1 Study
PRESS RELEASE published on 08/15/2024 at 13:00, 3 months 8 days ago CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board CureVac appoints Dr. Mehdi Shahidi, an expert in oncology and drug development, as independent director to its Supervisory Board, enhancing focus on mRNA-based cancer vaccines Oncology Drug Development CureVac MRNA Dr. Mehdi Shahidi
BRIEF published on 07/11/2024 at 13:05, 4 months 12 days ago CureVac Updates Trial Dates for Patent Litigation Against Pfizer/BioNTech CureVac Patent Litigation Legal Update Pfizer/BioNTech Trial Dates
PRESS RELEASE published on 07/11/2024 at 13:00, 4 months 12 days ago CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech CureVac provides trial date updates for patent litigation against Pfizer/BioNTech in multiple geographies, including the U.S., UK, and Germany BioNTech CureVac Patent Litigation Pfizer Trial Dates
BRIEF published on 07/03/2024 at 08:17, 4 months 20 days ago CureVac Announces Strategic Restructuring to Focus on High-Value mRNA Opportunities Licensing Agreement MRNA Technology Oncology Research Strategic Restructuring Workforce Reduction
BRIEF published on 07/03/2024 at 08:14, 4 months 20 days ago GSK and CureVac to Restructure Collaboration into New Licensing Agreement Licensing Agreement GSK CureVac MRNA Vaccines
PRESS RELEASE published on 07/03/2024 at 08:12, 4 months 20 days ago CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities CureVac initiates strategic restructuring to focus on high-value mRNA pipeline opportunities, including workforce reduction and new GSK agreement Oncology Strategic Restructuring CureVac MRNA Pipeline GSK Agreement
PRESS RELEASE published on 07/03/2024 at 08:09, 4 months 20 days ago GSK and CureVac to Restructure Collaboration into New Licensing Agreement GSK and CureVac restructure collaboration into new licensing agreement for mRNA vaccines development, manufacturing, and commercialization globally Licensing Agreement Collaboration GSK MRNA Vaccines CureVac
BRIEF published on 06/24/2024 at 22:10, 4 months 29 days ago CureVac Announces Voting Results of General Meeting Annual General Meeting Voting Results Board Appointments CureVac MRNA
PRESS RELEASE published on 06/24/2024 at 22:05, 4 months 29 days ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of the general meeting, including board appointments and auditor reappointment. Shareholders voted in favor of all proposals Appointments Voting Results General Meeting CureVac Auditor Reappointment
Published on 11/22/2024 at 23:55, 1 day 3 hours ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 1 day 3 hours ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 1 day 4 hours ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 1 day 4 hours ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:14, 1 day 9 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 1 day 9 hours ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 1 day 10 hours ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/21/2024 at 06:58, 2 days 20 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 3 days 7 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 3 days 9 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 3 days 9 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
